Company Profile Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products. Its products include Swoop Portable MR imaging system, which offers neuroimaging at the point of care. The company was incorporated in 2014 and is based in Guilford, Connecticut.
Casey's General Stores, Inc. (CASY) NasdaqGS - NasdaqGS Real Time Price. 284.49+10.68 (+3.90%) As of 09:42AM EST. Van and I both like this name.
I like RTX better. Raytheon. $81. We missed the big move on the bounce. I got in last month just over $79. IRA, not a trade.
These pet super-stores... like Petsmart... I don't think they're gonna make it. Chewy and Amazon smoke them on price. Plus they need tons of employees to take care of everything. There were like 3 customers in there yesterday, 20 employees.
I realize some of the stuff I say is easier said than done-- Take this name IOVA- I have owned it three times and I have lost money two of the three times. They have never given me much hope. And I don't particularly like them but the early stats on their breast cancer drug were very very good but it has taken too long and the stk is too dead etc. Also the idea of using one's own stuff to fight cancer I am high on vs pouring tons of chemicals into the body... Right now, Iovance Biotherapeutics (NASDAQ: IOVA) stock can be purchased for a fraction of its true value, at least according to investment bank analysts on Wall Street. The consensus price target on the stock implies a gain of 219% in 2024. Even a relatively conservative estimate from Goldman Sachs suggests the stock can shoot 88% higher over the next 12 months or so. Why Wall Street's pounding the table on Iovance Biotherapeutics stock Iovance Biotherapeutics is pioneering a new approach to cancer treatment that uses the power of naturally occurring immune cells called tumor-infiltrating lymphocytes. An application for its first drug, called lifileucel, is under review by the U.S. Food and Drug Administration (FDA). Immune checkpoint inhibitors such as Keytruda have been life savers for patients with melanoma and other solid tumors. Unfortunately, many who receive them still experience disease progression. Wall Street is excited about Iovance because it looks like its cell-based therapy can become a new option for hard-to-treat patients who relapse despite standard care. During a clinical trial supporting the application currently under review, a subgroup of patients with cases of advanced mucosal melanoma that worsened despite treatment with checkpoint inhibitors showed eye-popping results. At a median follow-up of 35.7 months, lifileucel shrank tumors for half of the subgroup, including one patient who achieved complete remission. After this news I lost money! Shrinking tumors is a step in the right direction, but it isn't much good if the disease comes roaring right back. Among the six patients with advanced mucosal melanoma who initially responded to treatment with lifileucel, four were still responding at the 24-month checkup. In other words, it looks like this treatment gives patients who have run out of options a strong chance for long-term survival. The FDA is expected to announce an approval decision regarding lifileucel as a treatment for melanoma on or before Feb. 24, 2024. Melanoma could be just the beginning, too. The company is also enrolling cervical cancer patients into a clinical trial that could support an expansion in the not-too-distant future. The Wall Street analysts who set lofty price targets on Iovance are assuming lifileucel will inspire a huge buyout offer from a big pharmaceutical company that wants to expand its oncology presence. Given the mergers and acquisitions activity we've seen recently, it's not a farfetched proposition. Hummmmmmmmmmmm. Confused Person looking at stock charts on computer. Is Iovance Biotherapeutics a good investment now? Lifileucel might excite oncologists and Wall Street analysts, but sales will likely be muted, because this isn't a prescription that can be filled by your everyday pharmacy. A new batch of lifileucel must be manufactured from stem cells after those cells have been harvested from each new patient. Sales of complex cellular cancer therapies have been improving slowly since the FDA approved Yescarta from Gilead Sciences in 2017, but they're still low enough to make big pharma think twice before making any buyout offers. Gilead currently markets two cell-based cancer therapies with sales that reached a combined $1.4 billion in the first nine months of 2023. At recent prices, Iovance Biotherapeutics sports a $1.6 billion market cap. The company has no products to sell yet, and its cash balance dwindled to $428 million at the end of September after it lost $328 million in the first nine months of 2023. Iovance said that all pre-approval inspections of clinical sites and manufacturing facilities have been completed successfully. While this is likely true, investors should understand that we only have the company's side of the story. The FDA can't comment on pending drug applications, even if applicants make misleading statements to investors. If the FDA delays approval of lifileucel, again, <----- this stock will fall hard. Analysts aren't wrong to predict a big gain in 2024, but this stock is only appropriate for investors with a high tolerance for risk. And it's probably too risky for me.
We have a super large Petco that took over this uber gorgeous building right on the park at 14 st Union Square. I can't believe they took the space. Looks like they put corporate in there too and they have weird specialized Dog stuff -- trying to be more into pet care and bathing and cutting and maybe even housing-- I haven't gone in the store.
Yeah I think the one we went into yesterday had a vet clinic, but it looked like it was closed. The lights were out. That collar was $29 lol. I'm sure it's probably $18 on AMZN. Going in there (and the collar) was Yulias idea. Ya know as much as she bitches about Muttley, ie the shedding and my new fascination with homeade dogfood ruining pots, and "you go to the store to buy 5#'s of brown rice and 10 cans of salmon" --- I read it as she secretly loves Muttley too.The reflective collar to keep her safe.